| BRAF gene and melanoma: Back to the future M Ottaviano, EF Giunta, M Tortora, M Curvietto, L Attademo, D Bosso, ... International Journal of Molecular Sciences 22 (7), 3474, 2021 | 60 | 2021 |
| Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials EF Giunta, G Bregni, A Pretta, A Deleporte, G Liberale, AM Bali, L Moretti, ... Cancer treatment reviews 96, 102177, 2021 | 52 | 2021 |
| A preliminary study for quantitative assessment with HFUS (High-Frequency Ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary … A Reginelli, MP Belfiore, A Russo, F Turriziani, E Moscarella, T Troiani, ... Current radiopharmaceuticals 13 (1), 48-55, 2020 | 49 | 2020 |
| Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations EF Giunta, V De Falco, S Napolitano, G Argenziano, G Brancaccio, ... Therapeutic Advances in Medical Oncology 12, 1758835920925219, 2020 | 41 | 2020 |
| Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience PP Vitiello, V De Falco, EF Giunta, D Ciardiello, C Cardone, P Vitale, ... Cancers 11 (10), 1504, 2019 | 39 | 2019 |
| Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression S Napolitano, N Matrone, AL Muddassir, G Martini, A Sorokin, V De Falco, ... Journal of Experimental & Clinical Cancer Research 38, 1-18, 2019 | 30 | 2019 |
| Cancer treatment–induced bone loss (CTIBL): State of the art and proper Management in Breast Cancer Patients on endocrine therapy A Diana, F Carlino, EF Giunta, E Franzese, LP Guerrera, V Di Lauro, ... Current Treatment Options in Oncology 22 (5), 45, 2021 | 29 | 2021 |
| Epigenetic regulation in melanoma: facts and hopes EF Giunta, G Arrichiello, M Curvietto, A Pappalardo, D Bosso, ... Cells 10 (8), 2048, 2021 | 28 | 2021 |
| Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients EF Giunta, G Barra, V De Falco, G Argenziano, S Napolitano, P Vitale, ... Scientific Reports 10 (1), 17626, 2020 | 28 | 2020 |
| Anorectal and genital mucosal melanoma: diagnostic challenges, current knowledge and therapeutic opportunities of rare melanomas M Ottaviano, EF Giunta, L Marandino, M Tortora, L Attademo, D Bosso, ... Biomedicines 10 (1), 150, 2022 | 19 | 2022 |
| Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer PP Vitiello, G Martini, L Mele, EF Giunta, V De Falco, D Ciardiello, V Belli, ... Journal of Experimental & Clinical Cancer Research 40, 1-15, 2021 | 18 | 2021 |
| Adjuvant treatment in pancreatic cancer: shaping the future of the curative setting A Pappalardo, EF Giunta, G Tirino, L Pompella, P Federico, B Daniele, ... Frontiers in Oncology 11, 695627, 2021 | 18 | 2021 |
| Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’ V De Falco, L Poliero, PP Vitiello, D Ciardiello, P Vitale, N Zanaletti, ... ESMO open 5 (2), e000675, 2020 | 18 | 2020 |
| Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models V Belli, N Matrone, S Napolitano, G Migliardi, F Cottino, A Bertotti, ... Journal of Experimental & Clinical Cancer Research 38, 1-14, 2019 | 18 | 2019 |
| Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature G Viscardi, N Zanaletti, MG Ferrara, A Sica, U Falcone, S Guastafierro, ... ESMO open 4 (5), e000551, 2019 | 16 | 2019 |
| Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients T Troiani, EF Giunta, M Tufano, V Vigorito, PD Arrigo, G Argenziano, ... British Journal of Cancer 122 (12), 1782-1790, 2020 | 15 | 2020 |
| Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: A review of the current evidence SE Rebuzzi, GL Banna, V Murianni, A Damassi, EF Giunta, F Fraggetta, ... Cancers 13 (21), 5517, 2021 | 14 | 2021 |
| Tackling refractory metastatic colorectal cancer: future perspectives N Personeni, V Smiroldo, EF Giunta, MG Prete, L Rimassa, G Bregni, ... Cancers 13 (18), 4506, 2021 | 14 | 2021 |
| Bone metastases from gastric cancer: what we know and how to deal with them A Petrillo, EF Giunta, A Pappalardo, D Bosso, L Attademo, C Cardalesi, ... Journal of Clinical Medicine 10 (8), 1777, 2021 | 12 | 2021 |
| Adherence to oral treatments in older patients with advanced prostate cancer, the ADHERE Study: A prospective trial of the Meet-URO network P Rescigno, M Maruzzo, SE Rebuzzi, V Murianni, M Cinausero, H Lipari, ... The Oncologist 27 (12), e949-e956, 2022 | 11 | 2022 |
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoli在 unina2.it 的电子邮件经过验证
